| Literature DB >> 34150337 |
Barry Power1,2, Aaron Donnelly1, Conor Murphy1, Timothy Fulcher2, William Power1.
Abstract
OBJECTIVES: To compare presentation of infectious keratitis during COVID-19 lockdown with previous years, assess relative severity, and compare outcomes between COVID-19 and pre-COVID-19 era groups.Entities:
Year: 2021 PMID: 34150337 PMCID: PMC8197668 DOI: 10.1155/2021/5514055
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Risk factors.
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Total corneal C + S | 29 | 47 | 45 |
|
| |||
| Risk factor | |||
| CL use | 9 (31) | 16 (34) | 12 (28) |
| Corneal surface disease | 2 (7) | 2 (4) | 4 (9) |
| Previous corneal surgery | 3 (10) | 3 (6) | 2 (4) |
| RCES | 1 (3) | 0 | 0 |
| Previous keratitis | 1 (3) | 1 (2) | 0 |
| Neurotrophic cornea | 2 (7) | 7 (15) | 2 (4) |
| Trauma | 0 | 2 (4) | 3 (7) |
C + S, culture and sensitivity; RCES, recurrent corneal erosion syndrome.
Clinical details.
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Admitted | 15 (52) | 29 (62) | 29 (69) |
|
| |||
| Treatment | |||
| Cef/Vanc | 13 (45) | 25 (53) | 28 (64) |
| Ofloxacin | 14 (48) | 17 (36) | 7 (16) |
| Brolene/PHMB | 1 (3) | 3 (6) | 1 (2) |
| Anti viral | 0 | 5 (11) | 5 (11) |
| Anti fungal | 1 (3) | 2 (4) | 1 (2) |
| Not recorded | 0 | 0 | 3 (7) |
Treatment, all patients receiving described treatment, including combination therapy. Cef/Vanc, ceftazidime/vancomycin; PHMB, polyhexamethylene biguanide; others, antifungal and antiviral therapy.
Outcomes.
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Mean LogMAR BCVA | |||
| Presentation | 1.04 | 1.16 | 1.15 |
| Final | 0.78 | 0.49 | 0.7 |
| Change | 0.26 | 0.67 | 0.45 |
|
| |||
| Surgical intervention | 3 (10) | 2 (4) | 1 (2) |
BCVA, best-corrected visual acuity. P value = 0.04.
Microbiologic profiles of corneal cultures.
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Cultures taken | 29 | 47 | 45 |
|
| |||
| Positive culture | 9 (31%) | 23 (49%) | 25 (56%) |
|
| |||
| Gram-positive | 3 (33) | 12 (52) | 13 (52) |
| | 0 | 2 (9) | 2 (8) |
| | 2 (22) | 3 (13) | 5 (20) |
| | 0 | 6 (26) | 3 (12) |
| Othersa | 1 (11) | 1 (4) | 3 (12) |
|
| |||
| Gram-negative | 5 (55) | 9 (39) | 10 (40) |
|
| 0 | 1 (4) | 1 (4) |
|
| 5 (55) | 6 (26) | 6 (24) |
| Othersb | 0 | 2 (9) | 1 (4) |
|
| |||
| Fungi | 1 (11) | 2 (9) | 1 (4) |
| Yeast | 1 (11) | 0 | 1 (4) |
| Filamentous | 0 | 1 (4) | 0 |
|
| |||
| Acanthamoeba | 0 | 1 (4) | 1 (4) |
aOthers, Gram-positive organisms included Corynebacterium striatum, Diphtheroids, Propionibacterium, and Micrococcus luteus. bOthers, Gram-negative organisms included Stenotrophomonas and Serratia.